Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1508 ARTÍCULOS , VIENDO DEL 391 AL 405

Neuroproteomic tools for battling Alzheimer's disease

Veenstra TD.

Proteomics. 2016 Nov;16(22):2847-2853. doi: 10.1002/pmic.201600211. Epub 2016 Oct 14.

Role of gut microbiota and nutrients in amyloid formation and pathogenesis of Alzheimer disease

Pistollato F, Sumalla Cano S, Elio I, Masias Vergara M, Giampieri F, Battino M.

Nutr Rev. 2016 Oct;74(10):624-34. doi: 10.1093/nutrit/nuw023.

Translational Assays for Assessment of Cognition in Rodent Models of Alzheimer's Disease and Dementia

Shepherd A, Tyebji S, Hannan AJ, Burrows EL.

J Mol Neurosci. 2016 Nov;60(3):371-382. doi: 10.1007/s12031-016-0837-1. Epub 2016 Sep 16.

Drug development in Alzheimer's disease: the path to 2025

Cummings J, Aisen PS, DuBois B, Frölich L, Jack CR Jr, Jones RW, Morris JC, Raskin J, Dowsett SA, Scheltens P.

Alzheimers Res Ther. 2016 Sep 20;8:39. doi: 10.1186/s13195-016-0207-9.

The Complex Role of Apolipoprotein E in Alzheimer's Disease: an Overview and Update

Mahoney-Sanchez L, Belaidi AA, Bush AI, Ayton S.

J Mol Neurosci. 2016 Nov;60(3):325-335. doi: 10.1007/s12031-016-0839-z. Epub 2016 Sep 19.

Comparative study of false memory in dementia with Lewy bodies and Alzheimer's disease

Phillipps C, Kemp J, Jacob C, Veronneau A, Albasser T, Philippi N, Cretin B, Bernard F, Blanc F.

Geriatr Psychol Neuropsychiatr Vieil. 2016 Sep 1;14(3):332-40. doi: 10.1684/pnv.2016.0620.

Interactions between inflammation, sex steroids, and Alzheimer's disease risk factors

Uchoa MF, Moser VA, Pike CJ.

Front Neuroendocrinol. 2016 Oct;43:60-82. doi: 10.1016/j.yfrne.2016.09.001. Epub 2016 Sep 17.

Spices: Potential Therapeutics for Alzheimer's Disease

Satheeshkumar N, Vijayan RS, Lingesh A, Santhikumar S, Vishnuvardhan Ch.

Adv Neurobiol. 2016;12:57-78. doi: 10.1007/978-3-319-28383-8_4.

Alzheimer's Disease and Medicinal Plants: An Overview

Manoharan S, Essa MM, Vinoth A, Kowsalya R, Manimaran A, Selvasundaram R.

Adv Neurobiol. 2016;12:95-105. doi: 10.1007/978-3-319-28383-8_6.

Potential of the Antibody Against cis-Phosphorylated Tau in the Early Diagnosis, Treatment, and Prevention of Alzheimer Disease and Brain Injury

Lu KP, Kondo A, Albayram O, Herbert MK, Liu H, Zhou XZ.

JAMA Neurol. 2016 Nov 1;73(11):1356-1362. doi: 10.1001/jamaneurol.2016.2027.

Multitasking Microglia and Alzheimer's Disease: Diversity, Tools and Therapeutic Targets

Grubman A, Kanninen KM, Malm T.

J Mol Neurosci. 2016 Nov;60(3):390-404. doi: 10.1007/s12031-016-0825-5. Epub 2016 Sep 22.

Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer's disease patients

Panza F, Seripa D, Solfrizzi V, Imbimbo BP, Lozupone M, Leo A, Sardone R, Gagliardi G, Lofano L, Creanza BC, Bisceglia P, Daniele A, Bellomo A, Greco A, Logroscino G.

Expert Opin Emerg Drugs. 2016 Dec;21(4):377-391. doi: 10.1080/14728214.2016.1241232. Epub 2016 Oct 6.

Interleukin-8 gene polymorphism -251T>A contributes to Alzheimer's disease susceptibility

Qin B, Li L, Wang S, Wu J, Huang Y, Zhou P, Bai J, Zheng Y.

Medicine (Baltimore). 2016 Sep;95(39):e5039. doi: 10.1097/MD.0000000000005039.

An Update on Biomedical Application of Nanotechnology for Alzheimer's Disease Diagnosis and Therapy

Panahi Y, Mohammadhosseini M, Abadi AJ, Akbarzadeh A, Mellatyar H.

Drug Res (Stuttg). 2016 Nov;66(11):580-586. doi: 10.1055/s-0042-112811. Epub 2016 Oct 4.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias